Protecting Canadians from excessive drug prices : consulting on proposed amendements to the Patented Medicines Regulations.: H82-28/2017E-PDF
"In January 2016, federal, provincial and territorial Ministers agreed to work together to improve the affordability, accessibility and appropriate use of prescription drugs to better meet health care system needs. ... This important work includes reducing the cost of patented drugs through the modernization of the pricing framework under the Patented Medicine Prices Review Board (PMRPB). Under the authority of the Patent Act and through the Patented Medicines Regulations (“Regulations”), the Government of Canada regulates the prices of patented medicines in Canada to ensure that prices are not excessive. Despite significant changes in the pharmaceutical market, the regulations have not been substantively changed in over two decades. Health Canada is consulting stakeholders and interested members of the public on proposed amendments to the Regulations, to equip the PMPRB with more relevant and effective regulatory tools to better protect Canadians from excessive prices for patented drugs. ... Feedback received on or before June 28th, 2017, will be considered in developing a regulatory proposal under the Patent Act to protect Canadians from excessive drug prices. A summary of comments will be published in the RIAS statement at Canada Gazette, Part I"--p. 3 and p. 16.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.837289&sl=0
| Department/Agency | Canada. Health Canada. |
|---|---|
| Collaborating author | Canada. Patented Medicine Prices Review Board. |
| Title | Protecting Canadians from excessive drug prices : consulting on proposed amendements to the Patented Medicines Regulations. |
| Variant title | Consulting on proposed amendements to the Patented Medicines Regulations |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Cover title. "This consultation period is 6 weeks, running from May 16, 2017 to June 28, 2017"--p. 5. Issued also in French under title: Protéger les Canadiens des prix excessifs des médicaments : consultation sur les modificaations proposées au Règlement sur les médicaments brevetés. Includes bibliographical references. |
| Publishing information | [Ottawa] : Health Canada, 2017. |
| Description | 16 p. : col. ill. |
| Catalogue number |
|
| Subject terms | Drugs Price regulation Reform Consultations |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: